ClinicalTrials.gg
CompletedNCT02680756Updated Nov 2, 2020Results posted

Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

A Phase 3 interventional study of Ferric Maltol and Ferric Carboxy Maltose in Anemia, Iron-Deficiency, Inflammatory Bowel Disease and Crohn's Disease, sponsored by Shield Therapeutics. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.

Sponsored by Shield Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing ferric maltol in Anemia, Iron-Deficiency — none open to participants now, none under way, none of them phase 3. ferric maltol · Anemia, Iron-Deficiency.

Enrollment
Largest of 12
250 · median 78
Started
2016
with 1 other
Phase 3
7 of 12
none open now
Registered
3rd of 12
by date
Lead sponsor
7 of 12
Shield Therapeutics

Among the 12 studies testing ferric maltol in Anemia, Iron-Deficiency, this one has the largest enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 3rd registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

None of the 12 studies testing ferric maltol in Anemia, Iron-Deficiency is open now. The open studies under Anemia, Iron-Deficiency, anywhere →

About ferric maltol

ferric maltol: first FDA approval 2019 (ACCRUFER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing ferric maltol in Anemia, Iron-Deficiency as a file.
02

Study summary

The purpose of this study is to compare the efficacy of ferric maltol and intravenous iron (IVI) Ferric Carboxy Maltose in the treatment of iron deficiency anaemia (IDA) and subsequent maintenance of haemoglobin in subjects with Inflammatory Bowel Disease (IBD).

Read the detailed description

A phase 3b, randomized, controlled, multicentre study with oral ferric maltol or intravenous iron (FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease.

Approximately 242 eligible subjects will be randomised (1:1) to receive one of the following treatments for the duration of the study treatment period (52 weeks):

  • Oral ferric maltol, 30 mg capsule bid.
  • Intravenous iron (ferric carboxy maltose) as per SPC

In the FCM arm IV iron treatment will be repeated if the subject is iron deficient at any of the study visits.

Subject participation in the study will consist of 3 periods:

  • Screening: Up to 14 days
  • Randomised Treatment: 52 weeks
  • Post-treatment safety follow-up: 14 days after study medication discontinuation

Primary efficacy and safety of ferric maltol and Intravenous iron (ferric carboxy maltose) will be evaluated after the first 12 weeks.

End of study evaluations will occur at Week 52 or premature discontinuation.

03

Conditions studied

  • Anemia, Iron-Deficiency
  • Inflammatory Bowel Disease
  • Crohn's Disease

Keywords

  • Iron Deficiency
  • Anaemia
  • Crohn's Disease
  • Deficiency Diseases
  • Inflammatory Bowel Diseases
  • Intestinal Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

All of the following criteria must be met to randomize a subject in the study:

  1. Subjects must be competent to understand the information given in the Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved form and must sign and date the informed consent prior to any study mandated procedure
  2. Subjects must be willing and able to comply with study requirements
  3. Age ≥ 18 years
  4. Subjects must have a confirmed diagnosis of IBD (endoscopic and/or )
  5. Subjects must be considered suitable for intravenous iron treatment by the Investigator
  6. Subjects must have iron deficiency anaemia defined by the following criteria:

    1. 8.0 g/dL and ≤11.0 g/dL for women OR a Hb 8.0 g/dL and ≤12.0 g/dL for men
    2. AND Ferritin \<30ng/ml OR Ferritin \<100 ng/ml WITH Transferrin saturation (TSAT) \<20%
  7. Female subjects of (including perimenopausal females who have had a menstrual period within 1 year prior to screening) must agree to use a reliable method of until they have completed the study and for at least 4 weeks following their final study visit. Reliable contraception is defined as a method which results in a low failure rate, i.e., less than 1% per year when used consistently and correctly, such as implants, injectables, some intrauterine contraceptive devices (IUDs), complete sexual abstinence, or a vasectomized partner. Oral contraceptive medications are allowed in this study. Female subjects who are surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or (defined as no menstrual period within 1 year of screening) are also allowed to participate.

A subject who meets any of the following criteria is not eligible for participation in the study.

  1. Subject with anaemia due to any cause other than iron deficiency, including, but not limited to:

    1. Untreated or untreatable severe malabsorption syndrome
    2. use. Immunosuppressants are permitted so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis.

    Variations to dosing are permitted at the discretion of the investigator so long as there is no clinical evidence or suspicion of the immunosuppressant contributing to the subject's anaemia or affecting erythropoiesis

  2. Subject who has received prior to screening:

    1. Within 8 weeks intramuscular or intravenous (IV) iron or administration of depot iron preparation
    2. Within 2 weeks a blood transfusion
    3. Oral iron supplementation, taken specifically to treat anaemia, within the previous 4 weeks (Over the Counter (OTC) multivitamins containing iron are permitted)
  3. Subjects with active inflammatory bowel disease as defined by a SCCAI score greater than 5 at Screening or a CDAI score greater than 300 in the Screening period (as assessed using the Screening haematocrit (HCT) and CDAI diary card completed by the subject for 7 days prior to planned randomization).
  4. Subjects with known or allergy to either the active substance or of ferric maltol capsules or ferric carboxymaltose solution for IV administration
  5. Subjects who have had serious adverse reactions to previous doses of ferric carboxymaltose or any other intravenous iron.
  6. Subjects with for treatment with iron preparations, e.g. hemochromatosis, chronic hemolytic disease, sideroblastic anaemia, thalassemia, or lead intoxication induced anaemia.
  7. Subjects with vitamin B12 or folic acid deficiency as determined by the central laboratory screening results. Subjects may start vitamin B12 or folate replacement and rescreen after at least 2 weeks.
  8. Subjects who are pregnant or breast feeding.
  9. Concomitant medical conditions with significant active bleeding likely to initiate or prolong anaemia.
  10. Participation in any other interventional clinical study within 30 days prior to screening.
  11. Subject with cardiovascular, liver, renal, haematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease that, in the opinion of the Investigator, may adversely affect the safety of the subject or severely limit the lifespan of the subject (i.e. unlikely to complete the full duration of the study).
  12. Subject with significant neurologic or psychiatric symptoms resulting in disorientation, memory impairment, or inability to report accurately that might interfere with treatment compliance, study conduct or interpretation of the results (e.g., Alzheimer's disease, schizophrenia or other psychosis, active or current alcohol or drug abuse)
  13. Subject who is an inmate of a psychiatric ward, prison, or other state institution.
  14. Subject who is an Investigator or any other team member involved directly or indirectly in the conduct of the clinical study.
  15. Subjects with severe renal impairment: \<30 mL/min. (Applicable to US sites Only)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Oral ferric iron compound

    30 mg capsules to be taken orally twice a day for 52 weeks

    Drug: Ferric Maltol

  • Active comparator
    Intravenous iron

    Administered as per the local summary of product characteristics (SPC)

    Drug: Ferric Carboxy Maltose

Interventions

  • Also known as: Feraccru, Ferric Trimaltol, ST10, ST10-01

  • DrugFerric Carboxy Maltose
06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12

    Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women,\>=13g/dL men) at Week 12

    Time frame: Baseline to Week 12

  2. Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12

    Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women, \>=13g/dL men) at Week 12

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Hb Concentration From Baseline to Week 12

    Change in hemoglobin concentration from baseline to Week 12.

    Time frame: Baseline to Week 12

  2. Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL

    Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin \<9.5 g/dL.

    Time frame: Baseline to Week 12

  3. Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12

    Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.

    Time frame: Baseline to Week 12

  4. Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12

    Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.

    Time frame: Baseline to Week 12

  5. Number of Subjects With Hb Concentration Within Normal Limits at Week 12

    Number of subjects with Hb concentration within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

    Time frame: Baseline to Week 12

  6. Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 12

    Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

    Time frame: Baseline to Week 12

  7. Proportion of Subjects Who Are Non-anaemic at 6 Months and 12 Months

    Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 months and 12 months (normal limit definition: \>=12g/dL women, \>=13g/dL men)

    Time frame: Baseline to Month 6

  8. Change in Hb Concentration From Baseline to Week 4

    Change in hemoglobin concentration from baseline to Week 4.

    Time frame: Baseline to Week 4

  9. Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL

    Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin \<9.5 g/dL.

    Time frame: Baseline to Week 4

  10. Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12

    Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.

    Time frame: Baseline to Week 12

  11. Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12

    Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.

    Time frame: Baseline to Week 12

  12. Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4

    Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.

    Time frame: Baseline to Week 4

  13. Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4

    Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.

    Time frame: Baseline to Week 4

  14. Number of Subjects With Hb Concentration Within Normal Limits at Week 4

    Number of subjects with Hb concentration within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

    Time frame: Baseline to Week 4

  15. Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 4

    Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

    Time frame: Baseline to Week 4

  16. Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4

    Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.

    Time frame: Baseline to Week 4

  17. Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4

    Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4

    Time frame: Baseline to Week 4

Other outcomes

  1. Change From Baseline Physical Component and Mental Component Score

    A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research \& general population surveys. The SF-36 includes one multi-item scale that assesses 8 health components: Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; \& General Health Component. These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score \& the Physical Component Score where higher values mean a better outcome. Both scales range from 0 to 100, where higher scores indicate better health status. The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.

    Time frame: Baseline to Week 52 (LOCF)

  2. Number of Patients With Treatment-emergent Adverse Events (AEs)

    Number of Patients with Treatment-emergent Adverse Events (AEs).

    Time frame: Baseline to Week 52

  3. Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)

    Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).

    Time frame: Baseline to Week 52

07

Results

Posted Feb 24, 2020

Participant flow

Participant flow — Overall Study
MilestoneOral Ferric Iron CompoundIntravenous Iron
Started125125
Received treatment127120
Completed93106
Not completed3219
Withdrew: Adverse event102
Withdrew: Lost to follow-up76
Withdrew: Withdrawal by subject55
Withdrew: Physician decision41
Withdrew: Hb ≤7.5 g/dl02
Withdrew: Blood transfusion for any reason01
Withdrew: Death10
Withdrew: Protocol violation10
Withdrew: Tsat above 60% or a ferritin above 800 m10
Withdrew: None of above or not recorded32

Outcome measures

PrimaryNumber of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12

Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women,\>=13g/dL men) at Week 12

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder84105
Non-responder4120
Statistical analysis
  • Oral Ferric Iron Compound vs Intravenous Iron · t-test, 2 sided · p = 0.298 · Risk difference (rd): -0.17 · 95% CI -0.28 to -0.06
PrimaryNumber of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12

Number of subjects achieving either a 2g/dL increase in Hb OR normalization of Hb (\>=12g/dL women, \>=13g/dL men) at Week 12

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder5375
Non-responder2513
Statistical analysis
  • Oral Ferric Iron Compound vs Intravenous Iron · t-test, 2 sided · p = 0.341 · Risk difference (rd): -0.17 · 95% CI -0.30 to -0.05
SecondaryChange in Hb Concentration From Baseline to Week 12

Change in hemoglobin concentration from baseline to Week 12.

Time frame:
Baseline to Week 12
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 12
g/dLOral Ferric Iron CompoundIntravenous Iron
Change in Hb Concentration From Baseline to Week 122.45 ± 1.4493.04 ± 1.576
SecondaryChange in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL

Change in hemoglobin concentration from baseline to Week 12 in subjects with a baseline hemoglobin \<9.5 g/dL.

Time frame:
Baseline to Week 12
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL
g/dLOral Ferric Iron CompoundIntravenous Iron
Change in Hb Concentration From Baseline to Week 12 in Subjects With a Baseline Hb <9.5 g/dL2.83 ± 1.4934.18 ± 1.686
SecondaryNumber of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12

Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 12.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder107111
Non-responder1814
SecondaryNumber of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12

Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 12.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder3532
Non-responder33
SecondaryNumber of Subjects With Hb Concentration Within Normal Limits at Week 12

Number of subjects with Hb concentration within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects With Hb Concentration Within Normal Limits at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder69101
Non-responder5624
SecondaryNumber of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 12

Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 12 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder1228
Non-responder267
SecondaryProportion of Subjects Who Are Non-anaemic at 6 Months and 12 Months

Long term efficacy endpoints i.e. proportion of subjects who are non-anaemic at 6 months and 12 months (normal limit definition: \>=12g/dL women, \>=13g/dL men)

Time frame:
Baseline to Month 6
Reported as:
Count of participants · Participants
Proportion of Subjects Who Are Non-anaemic at 6 Months and 12 Months
ParticipantsOral Ferric Iron CompoundIntravenous Iron
week 24 — Non-anaemic5258
week 24 — Anaemic2827
week 52 — Non-anaemic3736
week 52 — Anaemic2420
SecondaryChange in Hb Concentration From Baseline to Week 4

Change in hemoglobin concentration from baseline to Week 4.

Time frame:
Baseline to Week 4
Reported as:
Mean · g/dL
Change in Hb Concentration From Baseline to Week 4
g/dLOral Ferric Iron CompoundIntravenous Iron
Change in Hb Concentration From Baseline to Week 41.27 ± 0.9742.19 ± 1.133
SecondaryChange in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL

Change in hemoglobin concentration from baseline to Week 4 in subjects with a baseline hemoglobin \<9.5 g/dL.

Time frame:
Baseline to Week 4
Reported as:
Mean · g/dl
Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL
g/dlOral Ferric Iron CompoundIntravenous Iron
Change in Hb Concentration From Baseline to Week 4 in Subjects With a Baseline Hb <9.5 g/dL1.35 ± 0.9932.99 ± 1.092
SecondaryNumber of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12

Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 12.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder7696
Non-responder4929
SecondaryNumber of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12

Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 12.

Time frame:
Baseline to Week 12
Reported as:
Count of participants · Participants
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 12
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder2630
Non-responder125
SecondaryNumber of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4

Number of subjects who experience a change from baseline in hemoglobin concentration ≥1.0 g/dL at Week 4.

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥1.0 g/dL at Week 4
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder75105
Non-responder5020
SecondaryNumber of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4

Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥1 g/dL at Week 4.

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥1 g/dL at Week 4
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder2231
Non-responder142
SecondaryNumber of Subjects With Hb Concentration Within Normal Limits at Week 4

Number of subjects with Hb concentration within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Hb Concentration Within Normal Limits at Week 4
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder3160
Non-responder9465
SecondaryNumber of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 4

Number of subjects with baseline Hb concentration \<9.5 g/dL that is within normal limits at Week 4 (normal limit definition: \>=12g/dL women, \>=13g/dL men)

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Baseline Hb Concentration <9.5 g/dL That is Within Normal Limits at Week 4
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder215
Non-responder3620
SecondaryNumber of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4

Number of subjects who experience a change from baseline in hemoglobin concentration ≥2.0 g/dL at Week 4.

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Subjects Who Experience a Change From Baseline in Hb Concentration ≥2.0 g/dL at Week 4
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder2675
Non-responder9950
SecondaryNumber of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4

Number of subjects with baseline hemoglobin \<9.5g/dL that achieve an increase in hemoglobin concentration of ≥2 g/dL at Week 4

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Subjects With Baseline Hb <9.5g/dL That Achieve an Increase in Hb Concentration of ≥2 g/dL at Week 4
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Responder528
Non-responder337
Other pre-specifiedChange From Baseline Physical Component and Mental Component Score

A multipurpose, proprietary health survey with 36 questions. It was constructed to survey health status in the Medical Outcomes Study and designed for use in clinical practice and research \& general population surveys. The SF-36 includes one multi-item scale that assesses 8 health components: Physical Functioning Component; Social Functioning Component; Role-Physical Component; Bodily Pain Component; Mental Health Component; Role-Emotional Component; Vitality Component; \& General Health Component. These 8 health component scales can be further summarised into 2 summary scores, the Mental Component Score \& the Physical Component Score where higher values mean a better outcome. Both scales range from 0 to 100, where higher scores indicate better health status. The survey will be administered at study visits as indicated in the schedule of assessments, commencing pre-randomization at Visit 2. The survey will be completed by the subjects in their native language.

Time frame:
Baseline to Week 52 (LOCF)
Reported as:
Mean · score on a scale
Change From Baseline Physical Component and Mental Component Score
score on a scaleOral Ferric Iron CompoundIntravenous Iron
Physical component score3.0 ± 7.622.5 ± 7.52
Mental component score3.3 ± 8.322.6 ± 7.60
Other pre-specifiedNumber of Patients With Treatment-emergent Adverse Events (AEs)

Number of Patients with Treatment-emergent Adverse Events (AEs).

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Patients With Treatment-emergent Adverse Events (AEs)
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Number of Patients With Treatment-emergent Adverse Events (AEs)7543
Other pre-specifiedNumber of Patients With Treatment-emergent Serious Adverse Events (SAEs)

Number of Patients with Treatment-emergent Serious Adverse Events (SAEs).

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)
ParticipantsOral Ferric Iron CompoundIntravenous Iron
Number of Patients With Treatment-emergent Serious Adverse Events (SAEs)93

Adverse events

Collected over The analysis of AEs focuses on TEAEs, which were defined as any AE that occurred on or worsened after the first dose of IMP and up to 14 days after the last dose of IMP (week 52 if study completed). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oral Ferric Iron Compound1/127 (0.8%)12/127 (9.4%)75/127 (59.1%)
Intravenous Iron0/120 (0%)4/120 (3.3%)43/120 (35.8%)
Most frequent serious events
Most frequent serious events
EventOral Ferric Iron CompoundIntravenous Iron
Gastrointestinal disordersGastrointestinal disorders3/1272/120
Infections and infestationsInfections and infestations3/1271/120
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications2/1270/120
Cardiac disordersCardiac disorders2/1270/120
Neoplasms benign, malignant and unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1271/120
Blood and lymphatic system disordersBlood and lymphatic system disorders1/1270/120
General disorders and administration site conditionsGeneral disorders1/1270/120
Psychiatric disordersPsychiatric disorders1/1270/120
Most frequent other events
Showing 10 of 29
Most frequent other events
EventOral Ferric Iron CompoundIntravenous Iron
Gastrointestinal disordersGastrointestinal disorders40/12715/120
Infections and infestationsInfections and infestations29/12722/120
Abdominal painGeneral disorders12/12715/120
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders11/1272/120
NasopharyngitisInfections and infestations10/1274/120
General disorders and administration site conditionsGeneral disorders9/1276/120
Nervous system disordersNervous system disorders9/1274/120
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders9/1274/120
Abdominal pain upperGastrointestinal disorders7/1272/120
Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications7/1272/120

Baseline characteristics

ITT

Age, Continuous
Age, Continuous(years)Oral Ferric Iron CompoundIntravenous IronTotal
Mean40.0 ± 14.5840.4 ± 15.5440.2 ± 15.04
Age, Customized
Age, Customized(years)Oral Ferric Iron CompoundIntravenous IronTotal
Age range40.0 (18 to 81)40.4 (19 to 77)40.2 (18 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Oral Ferric Iron CompoundIntravenous IronTotal
Female6877145
Male5748105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral Ferric Iron CompoundIntravenous IronTotal
Race — American Indian/Alaskan Native011
Race — Asian022
Race — Black/African American639
Race — White110111221
Race — Other8816
Race — Native American/Pacific Islander101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oral Ferric Iron CompoundIntravenous IronTotal
Ethnicity — Hispanic or Latino152035
Ethnicity — Not Hispanic or Latino9994193
Ethnicity — Not Reported8816
Ethnicity — Unknown336
Fertility status (females)
Fertility status (females)(Participants)Oral Ferric Iron CompoundIntravenous IronTotal
Sterile8614
Post-menopausal131629
Potentially fertile4654100
Not available112
Screening Hb for randomisation
Screening Hb for randomisation(Participants)Oral Ferric Iron CompoundIntravenous IronTotal
<10 g/dL Female or <11 g/dL Male6767134
≥10 g/dL Female or ≥11 g/dL Male5858116
Baseline Hb
Baseline Hb(Participants)Oral Ferric Iron CompoundIntravenous IronTotal
<9.5 g/dL383573
≥9.5 g/dL8790177

1 further baseline measures are reported on the registry.

08

Study locations

44 sites
  • Dothan, Alabama, United States
  • Tucson, Arizona, United States
  • Gainesville, Florida, United States
  • Hollywood, Florida, United States
  • Chevy Chase, Maryland, United States
  • Saint Paul, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Great Neck, New York, United States
  • Lima, Ohio, United States
  • Germantown, Tennessee, United States
  • Nashville, Tennessee, United States
  • Beaumont, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Bountiful, Utah, United States
  • Bellevue, Washington, United States
  • Seattle, Washington, United States
  • Gent, Belgium
  • Clichy, France
  • Lille, France
  • Lyon, France
  • Saint Etienne, France
  • Salouel, France
  • Vandœuvre-lès-Nancy, France
  • Berlin, Germany
  • Dresden, Germany
  • Hamburg, Germany
  • Herne, Germany
  • Jena, Germany
  • Leipzig, Germany
  • Lubeck, Germany
  • Luneburg, Germany
  • Minden, Germany
  • Oldenburg, Germany
  • Schweinfurt, Germany
  • Budapest, Hungary
  • Miskolc, Hungary
  • Szeged, Hungary
  • Barcelona, Spain
  • Cordoba, Spain
  • Girona, Spain
  • Madrid, Spain
  • Santiago de Compostela, Spain
  • Valencia, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Oct 2018, 33 months.

Results were first posted in Feb 2020, 1 year 4 months after primary completion.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2016
First posted
Feb 11, 2016
StartActual
Jan 2016
Primary completionActual
Oct 2018
CompletionActual
Jan 2019
Results first posted
Feb 24, 2020
Last update
Nov 2, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02680756
Lead sponsor
Shield Therapeutics
Responsible party
Sponsor
First posted
Feb 11, 2016
Start date
Jan 2016
Primary completion
Oct 2018
Completion
Jan 2019
Results posted
Feb 24, 2020
Last update
Nov 2, 2020

Study contacts

Jackie Mitchell, PhD
study director · Shield Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric maltol

Start the discussion